Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous dendritic cells with no mRNA transfection-Massachusetts General Hospital-HIV-1 infection
- Development stage
- Unknown
- Lead developer
- Massachusetts General Hospital
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intradermal
01
Overview
Autologous dendritic cells with no mRNA transfection refers to the control or placebo arm of a Phase 1/2 clinical trial (NCT00833781) conducted by Massachusetts General Hospital. In this study, patients with chronic HIV-1 infection on highly active antiretroviral therapy (HAART) received their own dendritic cells that were processed in the same manner as the active treatment but without the transfection of mRNA encoding HIV-1 antigens (Gag and Nef). This mock-transfected cell preparation served as a comparator to evaluate the safety and specific immunogenic effects of the active mRNA-transfected dendritic cell vaccine. The cells were administered via intradermal injection at multiple intervals.
- Other names
- mock-transfected autologous dendritic cellsautologous dendritic cells (no mRNA)
02
Targets
CCR7 (C-C Motif Chemokine Receptor 7)CD28 (Cluster of Differentiation 28)CD40LG (CD40 ligand extracellular domain)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)ICOS (Inducible T-cell costimulator)IL-12R (Interleukin-12 receptor)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on autologous dendritic cells with no mRNA transfection-Massachusetts General Hospital-HIV-1 infection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous dendritic cells with no mRNA transfection-Massachusetts General Hospital-HIV-1 infection.